Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000308245, designated as "novel transcript, antisense to CCR6", encodes a long non-coding RNA (lncRNA), not a protein. This RNA gene is classified as an antisense transcript relative to the *CCR6* gene but does not encode a known therapeutic target such as a receptor, enzyme, transporter, or similar protein. There are no reported biological functions, disease associations, interacting drugs, or known biomarker or safety data for this transcript[3]. It is not considered a canonical therapeutic target nor a protein-coding gene suitable for classical drug targeting. Further context: - The main functional and disease-related information available in the literature and databases refers to its sense counterpart, *CCR6* (C-C motif chemokine receptor 6)[1][2][7]. - The field of lncRNAs is rapidly evolving, but as of now, ENSG00000308245 lacks sufficient functional characterization. In summary, ENSG00000308245 ("novel transcript, antisense to CCR6") is a non-coding RNA gene and *not* a canonical therapeutic/protein target[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to CCR6.